Analysts Anticipate IVERIC bio Inc (NASDAQ:ISEE) Will Announce Earnings of -$0.28 Per Share

Wall Street analysts predict that IVERIC bio Inc (NASDAQ:ISEE) will post earnings per share (EPS) of ($0.28) for the current quarter, according to Zacks. Zero analysts have issued estimates for IVERIC bio’s earnings. IVERIC bio reported earnings of ($0.53) per share in the same quarter last year, which would indicate a positive year over year growth rate of 47.2%. The company is scheduled to announce its next earnings results before the market opens on Thursday, February 27th.

On average, analysts expect that IVERIC bio will report full-year earnings of ($1.34) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($1.27). For the next fiscal year, analysts expect that the company will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.55) to ($1.32). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for IVERIC bio.

Several equities research analysts have weighed in on ISEE shares. ValuEngine lowered IVERIC bio from a “sell” rating to a “strong sell” rating in a research report on Tuesday, February 4th. BidaskClub lowered IVERIC bio from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Wedbush started coverage on IVERIC bio in a research report on Monday, January 6th. They issued an “outperform” rating on the stock. Finally, Cowen started coverage on IVERIC bio in a research report on Friday, January 24th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $1.50.

In other news, Chairman David R. Guyer sold 9,275 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.60, for a total value of $61,215.00. Following the completion of the transaction, the chairman now owns 60,364 shares of the company’s stock, valued at $398,402.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman David R. Guyer sold 3,367 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $8.07, for a total value of $27,171.69. Following the completion of the transaction, the chairman now directly owns 57,339 shares of the company’s stock, valued at approximately $462,725.73. The disclosure for this sale can be found here. In the last three months, insiders sold 17,465 shares of company stock valued at $120,649. Company insiders own 4.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ISEE. Lindbrook Capital LLC bought a new position in IVERIC bio during the fourth quarter valued at about $26,000. Northern Trust Corp bought a new position in IVERIC bio during the second quarter valued at about $114,000. Alpine Global Management LLC bought a new position in IVERIC bio during the fourth quarter valued at about $151,000. Tower Research Capital LLC TRC boosted its stake in IVERIC bio by 11,914.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 18,382 shares of the company’s stock valued at $158,000 after buying an additional 18,229 shares in the last quarter. Finally, Laurion Capital Management LP bought a new position in IVERIC bio during the fourth quarter valued at about $242,000. 75.84% of the stock is owned by institutional investors.

Shares of ISEE stock traded up $0.04 on Friday, hitting $5.56. 444,300 shares of the stock traded hands, compared to its average volume of 549,021. The company has a market capitalization of $237.31 million, a PE ratio of 3.43 and a beta of 2.18. IVERIC bio has a 1-year low of $0.91 and a 1-year high of $8.97. The company’s fifty day moving average is $6.76 and its 200 day moving average is $3.92.

IVERIC bio Company Profile

IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).

Recommended Story: What is the definition of arbitrage?

Get a free copy of the Zacks research report on IVERIC bio (ISEE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.